Category - Developments

Developments

Kura Oncology reports positive Phase 2 data of tipifarnib in lymphoma

Kura Oncology (NASDAQ:KURA) provided updated interim data from its Phase 2 trial of tipifarnib in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

June 14, 2019

Developments

Progenics Pharma doses first prostate cancer patient in Phase 2 radiotherapy trial

Progenics Pharmaceuticals (NASDAQ:PGNX) dosed the first patient in a Phase 2 clinical study evaluating I-131 1095 radiotherapy for the treatment of metastatic castration resistant prostate cancer (mCRPC).

June 13, 2019

Developments

NuCana gets FDA’s orphan drug designation for acelarin

NuCana (NASDAQ:NCNA) received the FDA’s orphan drug designation for acelarin, a nucleoside analog of gemcitabine, for the treatment of biliary tract cancer.

June 13, 2019

Developments

InflaRx treats first pyoderma gangraenosum patient in Phase 2a trial

InflaRx (NASDAQ:IFRX) treated the first patient in a Phase 2a trial of IFX-1, an injectable antibody drug, in pyoderma gangraenosum (PG) patients.

June 13, 2019

Developments

Nuvectra seeking FDA conditional approval for full-body MR imaging for Algovita

Nuvectra (NASDAQ:NVTR) filed a regulatory submission with the FDA for conditional approval of full-body magnetic resonance (MR) imaging in patients implanted with the company’s Algovita spinal cord stimulation (SCS)...

June 12, 2019

Developments

ContraVir Pharma CRV431 data published in PLOS ONE

ContraVir Pharmaceuticals (NASDAQ:CTRV) CRV431 data from an experimental model of hepatitis B virus (HBV) has been published in the peer-reviewed journal, PLOS ONE.

June 11, 2019

Developments

Denali Therapeutics DNL310 gets FDA orphan drug and rare pediatric disease designations

Denali Therapeutics (NASDAQ:DNLI) received FDA orphan drug designation and rare pediatric disease designation for DNL310 for the treatment of Hunter syndrome.

June 11, 2019

Developments

FDA clears Ziopharm Oncology IND for T-cell receptor therapy

The FDA has cleared Ziopharm Oncology’s (NASDAQ:ZIOP) IND for its T-cell receptor therapy (TCR-T) for the treatment of solid tumors. Ziopharm’s TCR-T consists of T-cells that have been genetically modified to express...

June 11, 2019

Developments

Helius Medical PoNS study on brain activity in peer-reviewed journal

Helius Medical Technologies (NASDAQ:HSDT; TSX:HSM) reported that a scientific paper entitled, “Human Translingual Neurostimulation Alters Resting Brain Activity in High-density EEG,” was published in the latest edition...

June 11, 2019

Developments

IntelGenx to add Ottawa site to Montelukast VersaFilm Phase 2a trial; first patient in study completes treatment

IntelGenx (TSXV:IGX; OTCQX:IGXT) announced plans to add a new Ottawa site to its Montelukast VersaFilm Phase 2a clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD).

June 10, 2019

Category - Developments

Kura Oncology reports positive Phase 2 data of tipifarnib in lymphoma

Progenics Pharma doses first prostate cancer patient in Phase 2 radiotherapy trial

NuCana gets FDA’s orphan drug designation for acelarin

InflaRx treats first pyoderma gangraenosum patient in Phase 2a trial

Nuvectra seeking FDA conditional approval for full-body MR imaging for Algovita

ContraVir Pharma CRV431 data published in PLOS ONE

Denali Therapeutics DNL310 gets FDA orphan drug and rare pediatric disease designations

FDA clears Ziopharm Oncology IND for T-cell receptor therapy

Helius Medical PoNS study on brain activity in peer-reviewed journal

IntelGenx to add Ottawa site to Montelukast VersaFilm Phase 2a trial; first patient in study completes treatment

General

More